Lannett (NYSE: LCI) and Opko Health (NASDAQ:OPK) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, institutional ownership and valuation.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Lannett and Opko Health, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lannett 0 3 2 0 2.40
Opko Health 0 2 6 0 2.75

Lannett currently has a consensus target price of $21.50, suggesting a potential downside of 25.09%. Opko Health has a consensus target price of $14.81, suggesting a potential upside of 184.31%. Given Opko Health’s stronger consensus rating and higher possible upside, analysts clearly believe Opko Health is more favorable than Lannett.

Insider & Institutional Ownership

97.4% of Lannett shares are owned by institutional investors. Comparatively, 22.9% of Opko Health shares are owned by institutional investors. 15.0% of Lannett shares are owned by insiders. Comparatively, 40.2% of Opko Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

Lannett has a beta of 2.84, meaning that its share price is 184% more volatile than the S&P 500. Comparatively, Opko Health has a beta of 1.83, meaning that its share price is 83% more volatile than the S&P 500.


This table compares Lannett and Opko Health’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Lannett 6.67% 18.23% 6.16%
Opko Health -9.45% -5.17% -3.94%

Valuation & Earnings

This table compares Lannett and Opko Health’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Lannett $633.34 million 1.71 -$580,000.00 $1.12 25.63
Opko Health $1.22 billion 2.39 -$25.08 million ($0.22) -23.68

Lannett has higher earnings, but lower revenue than Opko Health. Opko Health is trading at a lower price-to-earnings ratio than Lannett, indicating that it is currently the more affordable of the two stocks.


Lannett beats Opko Health on 7 of the 13 factors compared between the two stocks.

Lannett Company Profile

Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules. The Company has additional products under development, which are orally administered solid oral-dosage products (tablet/capsule) or oral solutions, nasal, topicals or parentarels, as well as other dosage forms.

Opko Health Company Profile

OPKO Health, Inc. is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Through Bio-Reference, it operates laboratory divisions, such as Bio-Reference, GenPath (Oncology), GenPath (Women’s Health), GeneDx and Laboratorio Bueno Salud. As of December 31, 2016, it had one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Renal Products, Biologics, hGH-CTP, Factor VII, Oxyntomodulin, active pharmaceutical ingredients, Oligonucleotide Therapeutics, NK-1 Program, Asthma and chronic obstructive pulmonary disease.

Receive News & Ratings for Lannett Co Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett Co Inc and related companies with's FREE daily email newsletter.